首页> 外文期刊>JAMA: the Journal of the American Medical Association >Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase.
【24h】

Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase.

机译:与AmpCβ-内酰胺酶相关的国内获得性头孢曲松耐药沙门氏菌感染的出现。

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: Ceftriaxone, an expanded-spectrum cephalosporin, is an antimicrobial agent commonly used to treat severe Salmonella infections, especially in children. Ceftriaxone-resistant Salmonella infections have recently been reported in the United States, but the extent of the problem is unknown. OBJECTIVES: To summarize national surveillance data for ceftriaxone-resistant Salmonella infections in the United States and to describe mechanisms of resistance. DESIGN AND SETTING: Case series and laboratory evaluation of human isolates submitted to the Centers for Disease Control and Prevention from 17 state and community health departments participating in the National Antimicrobial Resistance Monitoring System (NARMS) for enteric bacteria between 1996 and 1998. PATIENTS: Patients with ceftriaxone-resistant Salmonella infections between 1996 and 1998 were interviewed and isolates with decreased ceftriaxone susceptibility were further characterized. MAIN OUTCOME MEASURES: Exposures and illness outcomes, mechanisms of resistance. RESULTS: The prevalence of ceftriaxone-resistant Salmonella was 0.1% (1 of 1326) in 1996, 0.4% (5 of 1301) in 1997, and 0.5% (7 of 1466) in 1998. Ten (77%) of the 13 patients with ceftriaxone-resistant infections were aged 18 years or younger. The patients lived in 8 states (California, Colorado, Kansas, Massachusetts, Maryland, Minnesota, New York, and Oregon). Nine (82%) of 11 patients interviewed did not take antimicrobial agents and 10 (91%) did not travel outside the United States before illness onset. Twelve of the 15 Salmonella isolates with ceftriaxone minimum inhibitory concentrations of 16 microg/mL or higher were serotype Typhimurium but these isolates had different pulsed-field gel electrophoresis patterns. Thirteen of these 15 isolates collected between 1996 and 1998 were positive for a 631-base pair polymerase chain reaction product obtained by using primers specific for the ampC gene of Citrobacter freundii. CONCLUSIONS: Domestically acquired ceftriaxone-resistant Salmonella has emerged in the United States. Most ceftriaxone-resistant Salmonella isolates had similar AmpC plasmid-mediated resistance.
机译:语境:头孢曲松钠是一种广谱头孢菌素,是一种通常用于治疗严重沙门氏菌感染(尤其是儿童)的抗菌剂。最近在美国报道了对头孢曲松耐药的沙门氏菌感染,但问题的严重程度尚不清楚。目的:总结美国对头孢曲松耐药沙门氏菌感染的国家监测数据,并描述耐药机制。设计与地点:1996年至1998年间,由参加国家肠道细菌耐药性监测系统(NARMS)的17个州和社区卫生部门向疾病控制和预防中心提交的人类分离株的病例系列和实验室评估。患者:患者对1996年至1998年间对头孢曲松耐药的沙门氏菌感染进行了采访,并对头孢曲松敏感性降低的分离株进行了进一步表征。主要观察指标:暴露和疾病结局,抵抗机制。结果:头孢曲松耐药沙门氏菌的患病率在1996年为0.1%(1326个中的1个),在1997年为0.4%(1301中的5个),在1998年为0.5%(1466个中的7个)。13例患者中有10个(77%)具有头孢曲松耐药性感染的患者年龄在18岁以下。患者居住在8个州(加利福尼亚州,科罗拉多州,堪萨斯州,马萨诸塞州,马里兰州,明尼苏达州,纽约州和俄勒冈州)。在接受采访的11位患者中,有9位(82%)未服用抗微生物剂,而10位(91%)在发病前未在美国以外旅行。头孢曲松的最低抑菌浓度为16 microg / mL或更高的15株沙门氏菌中有12株为鼠伤寒血清型,但这些菌株具有不同的脉冲场凝胶电泳图谱。在1996年至1998年之间收集的15株分离株中,有13株对631碱基对的聚合酶链反应产物呈阳性,该产物通过使用对弗氏柠檬酸杆菌ampC基因具有特异性的引物获得。结论:在美国已经出现了国内获得的对头孢曲松耐药的沙门氏菌。大多数对头孢曲松耐药的沙门氏菌分离株具有相似的AmpC质粒介导的耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号